These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

512 related items for PubMed ID: 34363769

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, van Eickels M, Gebel M, Zell E, Turpie AG.
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [Abstract] [Full Text] [Related]

  • 4. Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial.
    Ferro JM, Coutinho JM, Dentali F, Kobayashi A, Alasheev A, Canhão P, Karpov D, Nagel S, Posthuma L, Roriz JM, Caria J, Frässdorf M, Huisman H, Reilly P, Diener HC, RE-SPECT CVT Study Group.
    JAMA Neurol; 2019 Dec 01; 76(12):1457-1465. PubMed ID: 31479105
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK.
    Jugrin AV, Ustyugova A, Urbich M, Lamotte M, Sunderland T.
    Thromb Haemost; 2015 Oct 01; 114(4):778-92. PubMed ID: 26272227
    [Abstract] [Full Text] [Related]

  • 9. Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial.
    Bistervels IM, Buchmüller A, Wiegers HMG, Ní Áinle F, Tardy B, Donnelly J, Verhamme P, Jacobsen AF, Hansen AT, Rodger MA, DeSancho MT, Shmakov RG, van Es N, Prins MH, Chauleur C, Middeldorp S, Highlow Block writing committee, Highlow Investigators.
    Lancet; 2022 Nov 19; 400(10365):1777-1787. PubMed ID: 36354038
    [Abstract] [Full Text] [Related]

  • 10. Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
    Righini M, Galanaud JP, Guenneguez H, Brisot D, Diard A, Faisse P, Barrellier MT, Hamel-Desnos C, Jurus C, Pichot O, Martin M, Mazzolai L, Choquenet C, Accassat S, Robert-Ebadi H, Carrier M, Le Gal G, Mermilllod B, Laroche JP, Bounameaux H, Perrier A, Kahn SR, Quere I.
    Lancet Haematol; 2016 Dec 19; 3(12):e556-e562. PubMed ID: 27836513
    [Abstract] [Full Text] [Related]

  • 11. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
    Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, Lyons RM, Meijer K, Gudz I, Weitz JI, Zhang G, Lanz H, Mercuri MF, Büller HR, Hokusai-VTE investigators.
    Lancet Haematol; 2016 Aug 19; 3(8):e379-87. PubMed ID: 27476789
    [Abstract] [Full Text] [Related]

  • 12. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.
    Monagle P, Lensing AWA, Thelen K, Martinelli I, Male C, Santamaría A, Samochatova E, Kumar R, Holzhauer S, Saracco P, Simioni P, Robertson J, Grangl G, Halton J, Connor P, Young G, Molinari AC, Nowak-Göttl U, Kenet G, Kapsa S, Willmann S, Pap AF, Becka M, Twomey T, Beyer-Westendorf J, Prins MH, Kubitza D, EINSTEIN-Jr Phase 2 Investigators.
    Lancet Haematol; 2019 Oct 19; 6(10):e500-e509. PubMed ID: 31420317
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II.
    Goldhaber SZ, Schellong S, Kakkar A, Eriksson H, Feuring M, Kreuzer J, Fraessdorf M, Schulman S.
    Thromb Haemost; 2016 Sep 27; 116(4):714-21. PubMed ID: 27411591
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Managing pulmonary embolism from presentation to extended treatment.
    Cohen AT, Dobromirski M, Gurwith MM.
    Thromb Res; 2014 Feb 27; 133(2):139-48. PubMed ID: 24182642
    [Abstract] [Full Text] [Related]

  • 19. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
    Raskob G, Ageno W, Cohen AT, Brekelmans MP, Grosso MA, Segers A, Meyer G, Verhamme P, Wells PS, Lin M, Winters SM, Weitz JI, Büller HR.
    Lancet Haematol; 2016 May 27; 3(5):e228-36. PubMed ID: 27132697
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.